Background: The ability of antihyperuricemic therapy to exert renoprotective effects in patients with chronic\nkidney disease (CKD) is controversial. In the present study, we studied patient characteristics that may mask\nfavorable impact of antihyperuricemic therapy on the progression of CKD.\nMethods: This was a single-center, retrospective, follow-up study. One-hundred and seventy-eight CKD patients\nwith hyperuricemia who received febuxostat therapy were included in this study. Mean serum uric acid (mUA)\nlevel after treatment and changes in estimated glomerular filtration rate (Ã?â?eGFR) over 6 months were measured\nand their correlation was examined. Patients were divided into two groups based on mUA, and their Ã?â?eGFR\nwere compared. These analyses were evaluated in various subgroups.\nResults: Febuxostat therapy markedly decreased UA level in any CKD stage patients without resulting in serious\nadverse events. eGFRs of CKD patients in the mUA < 6.0 mg/dl group were maintained, whereas those in the\nmUA ââ?°Â¥ 6.0 mg/dl group decreased. A significant inverse correlation was observed between mUA and Ã?â?eGFR\n(r = âË?â??0.16, p = 0.019). The renoprotective effects of febuxostat were significant in the following subgroups: male\npatients, age < 70 years, systolic blood pressure < 130 mmHg, normal cholesterol levels, and absence of diabetes.\nCoexisting vascular risk factors appear to exert additive masking effects against febuxostat renoprotection.\nConclusions: The results of this study suggest that various vascular risk factors markedly attenuate the\nrenoprotective effects of febuxostat.
Loading....